CD274 and cancer: The results showed that MAGEA3 expression was significantly associated with 34 immune checkpoint markers, including PDCD1 (PD-1), CD274 (PD-L1), CTLA4, etc. As we have known, CD274 (PD-L1), CTLA4, and PDCD1 (PD-1) were biomarkers of response to ICI and already used in cancer immunotherapy (38–40).